Skip to main content
Premium Trial:

Request an Annual Quote

Olink Prices $264M Initial Public Offering

NEW YORK – Uppsala, Sweden-based proteomics firm Olink on Thursday priced its initial public offering of 17,647,058 common shares at $20 per share, for anticipated gross proceeds of $264.7 million before underwriting discounts, commissions, and other expenses.

The IPO includes 4,411,764 shares offered by the selling shareholders. Shares will be offered in the form of American depositary shares and are expected to begin trading on the Nasdaq Global Market under the symbol OLK on March 25, 2021.

The underwriters have been granted a 30-day option to purchase up to 2,647,058 additional shares from Knilo InvestCo, a selling shareholder. Knilo InvestCo, which is owned by Olink's current owner, private equity firm Summa Equity, will continue to be Olink's controlling shareholder.

Goldman Sachs and Morgan Stanley are acting as lead bookrunning managers for the offering, SVB Leerink as joint bookrunning manager, and BTIG as co-manager.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.